Basal Cell Carcinoma News and Research

RSS
Basal cell cancer begins in the lowest layer of the epidermis, the basal cell layer. About 8 out of 10 skin cancers are basal cell carcinomas. They usually begin on areas exposed to the sun, such as the head and neck. Basal cell carcinoma was once found mostly in middle-aged or older people. But now it is also being seen in younger people. This may be because people are spending more time in the sun without protecting their skin.

Basal cell carcinoma tends to grow slowly. It is very rare for a basal cell cancer to spread to distant parts of the body (metastasize). But if it is not treated, it can grow into nearby areas and spread into the bone or other tissues beneath the skin.

After treatment, basal cell carcinoma can come back (recur) in the same place on the skin. New basal cell cancers can also start in other places on the skin. As many as half of the people who have one basal cell cancer will get a new skin cancer within 5 years.
Combination therapy may help defeat pancreatic cancer

Combination therapy may help defeat pancreatic cancer

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

Erivedge drug shows promise against advanced basal cell carcinoma

Erivedge drug shows promise against advanced basal cell carcinoma

Imiquimod and PDT equivalent for superficial basal cell carcinoma

Imiquimod and PDT equivalent for superficial basal cell carcinoma

Painkillers may reduce skin cancer risk

Painkillers may reduce skin cancer risk

Common pain killers linked to decreased skin cancer risk

Common pain killers linked to decreased skin cancer risk

NSAIDs may offer protection against skin cancer

NSAIDs may offer protection against skin cancer

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

Austrian scientists challenge the clinical relevance of the term “basal-like” breast cancer subtype

Austrian scientists challenge the clinical relevance of the term “basal-like” breast cancer subtype

Electronic pathology report more accurately identifies nonmelanoma skin cancer

Electronic pathology report more accurately identifies nonmelanoma skin cancer

Hedgehog and mTOR pathway are active in esophageal cancer

Hedgehog and mTOR pathway are active in esophageal cancer

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

Genentech receives FDA approval for Vismodegib to treat skin cancer

Genentech receives FDA approval for Vismodegib to treat skin cancer

Roche’s skin cancer drug Erivedge gets FDA nod

Roche’s skin cancer drug Erivedge gets FDA nod

FDA approves Genentech's Erivedge for treatment of BCC

FDA approves Genentech's Erivedge for treatment of BCC

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Live interactive consultations can improve clinical outcomes for patients

Live interactive consultations can improve clinical outcomes for patients

Tanning beds raise risk of skin cancer – kids need to be barred

Tanning beds raise risk of skin cancer – kids need to be barred

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.